MX2023013114A - Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc. - Google Patents

Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc.

Info

Publication number
MX2023013114A
MX2023013114A MX2023013114A MX2023013114A MX2023013114A MX 2023013114 A MX2023013114 A MX 2023013114A MX 2023013114 A MX2023013114 A MX 2023013114A MX 2023013114 A MX2023013114 A MX 2023013114A MX 2023013114 A MX2023013114 A MX 2023013114A
Authority
MX
Mexico
Prior art keywords
taci
methods
dosing
treatment
immunomodulatory protein
Prior art date
Application number
MX2023013114A
Other languages
English (en)
Spanish (es)
Inventor
Jing Yang
Stacey Dillon
Stanford L Peng
Original Assignee
Alpine Immune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Immune Sciences Inc filed Critical Alpine Immune Sciences Inc
Publication of MX2023013114A publication Critical patent/MX2023013114A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023013114A 2021-05-07 2022-05-06 Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc. MX2023013114A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163186027P 2021-05-07 2021-05-07
US202163239899P 2021-09-01 2021-09-01
US202163256505P 2021-10-15 2021-10-15
US202163278072P 2021-11-10 2021-11-10
US202263329325P 2022-04-08 2022-04-08
PCT/US2022/072188 WO2022236335A1 (en) 2021-05-07 2022-05-06 Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein

Publications (1)

Publication Number Publication Date
MX2023013114A true MX2023013114A (es) 2023-11-17

Family

ID=81851023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013114A MX2023013114A (es) 2021-05-07 2022-05-06 Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc.

Country Status (13)

Country Link
US (1) US20240279310A1 (https=)
EP (1) EP4333869A1 (https=)
JP (1) JP2024518163A (https=)
KR (1) KR20240019124A (https=)
CN (3) CN119236055A (https=)
AU (1) AU2022269139A1 (https=)
CA (1) CA3216795A1 (https=)
CL (1) CL2023003301A1 (https=)
CO (1) CO2023016161A2 (https=)
IL (1) IL308336A (https=)
MX (1) MX2023013114A (https=)
PE (1) PE20240641A1 (https=)
WO (1) WO2022236335A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
KR20250057823A (ko) * 2022-08-29 2025-04-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Taci 폴리펩티드를 포함하는 융합 단백질 및 이의 용도
KR20250099778A (ko) * 2022-10-04 2025-07-02 알파인 이뮨 사이언시즈, 인코포레이티드 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질
WO2024114777A1 (zh) * 2022-12-02 2024-06-06 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗微小病变型肾病的方法
CN121152636A (zh) * 2023-07-06 2025-12-16 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法
WO2026008004A1 (zh) * 2024-07-04 2026-01-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
EP0584266B1 (en) 1991-05-06 2003-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
WO1996009380A1 (en) 1994-09-23 1996-03-28 The University Of British Columbia Method of enhancing expression of mhc class i molecules bearing endogenous peptides
DE69519521T2 (de) 1994-10-03 2001-06-28 The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
US6375952B1 (en) 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
SI1642972T1 (sl) 1999-01-07 2010-05-31 Zymogenetics Inc Terapevtske uporabe BR X topnih receptorjev
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
DE60235041D1 (de) 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
BRPI0711823A2 (pt) * 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
US20090186040A1 (en) * 2007-06-13 2009-07-23 Busby Sharon J DOSING METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-Ig FUSION PROTEIN SUCH AS ATACICEPT
CN101323643B (zh) 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
PL2222861T3 (pl) 2007-12-11 2018-04-30 The University Of North Carolina At Chapel Hill Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym
JP6017317B2 (ja) * 2011-02-02 2016-10-26 第一三共株式会社 ペプチド・ライブラリー
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
JP6355563B2 (ja) 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド Ｘｔｅｎ共役組成物およびそれを製造する方法
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
US10562954B2 (en) * 2014-05-12 2020-02-18 Shanghai Kanda Biotechnology Co., Ltd. Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
FI3380522T3 (fi) 2015-11-25 2024-01-16 Visterra Inc Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
EP4146684A2 (en) * 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof

Also Published As

Publication number Publication date
CA3216795A1 (en) 2022-11-10
IL308336A (en) 2024-01-01
CL2023003301A1 (es) 2024-06-21
JP2024518163A (ja) 2024-04-25
KR20240019124A (ko) 2024-02-14
WO2022236335A1 (en) 2022-11-10
PE20240641A1 (es) 2024-04-04
CN119236057A (zh) 2025-01-03
CN119236056A (zh) 2025-01-03
CO2023016161A2 (es) 2023-12-11
CN119236055A (zh) 2025-01-03
AU2022269139A1 (en) 2023-11-16
EP4333869A1 (en) 2024-03-13
US20240279310A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
MX2023013114A (es) Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc.
CL2022003104A1 (es) Proteínas inmunomoduladoras inhibidoras de april y baff y métodos de uso de las mismas
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
CO2017003070A2 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos
MX2019001223A (es) Moduladores de receptores de quimioquina y usos de los mismos.
CO2019000931A2 (es) Polipéptidos modificados y usos de los mismos
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
AR099101A1 (es) Dispositivo de fijación externo para tratar fracturas óseas
CR20210398A (es) Receptores que ofrecen coestimulación específica para terapia adoptiva de células
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
EA202091342A3 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112014031730A2 (pt) entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
EA201590881A1 (ru) Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
MX2025003628A (es) Métodos y usos de la proteína de fusión taci-fc inmunomoduladora
CO2021016860A2 (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
GT201500243A (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina
UY32641A (es) Compuestos con dos porciones heteroarilo bicíclicas fusionadas como moduladores de la hidrolasa de leucotrieno a4
BR112017012588B8 (pt) Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico
BR112016028888A2 (pt) compostos que compreendem o sistema 1,1',2,5'-tetra hidro espiro [indol-3,2'-pirrol]-2,5'-diona como inibidores de interação proteína-proteína p53-mdm2
PH12022551035A1 (en) Siglec-9 ecd fusion molecules and methods of use thereof